VERU INC. - COMMON STO

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

08 янв 2024 05:30:00 Источник Nasdaq GlobeNewswire

Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

19 дек 2023 05:30:00 Источник Nasdaq GlobeNewswire

Veru Announces Pricing of Public Offering of Common Stock

14 дек 2023 06:00:00 Источник Nasdaq GlobeNewswire

Veru Announces Proposed Public Offering of Common Stock

13 дек 2023 13:01:28 Источник Nasdaq GlobeNewswire

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study

04 окт 2023 05:30:00 Источник Nasdaq GlobeNewswire

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

26 сен 2023 05:30:00 Источник Nasdaq GlobeNewswire

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

20 сен 2023 05:30:00 Источник Nasdaq GlobeNewswire

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

11 сен 2023 04:00:00 Источник Nasdaq GlobeNewswire

Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023

30 авг 2023 05:30:00 Источник Nasdaq GlobeNewswire

Veru Reports Fiscal 2023 Third Quarter Financial Results

10 авг 2023 03:30:00 Источник Nasdaq GlobeNewswire

Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023

03 авг 2023 05:30:01 Источник Nasdaq GlobeNewswire

Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants

21 июн 2023 05:30:00 Источник Nasdaq GlobeNewswire

Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

01 июн 2023 05:30:00 Источник Nasdaq GlobeNewswire

Veru to Present at the Jefferies Healthcare Conference

24 май 2023 05:30:00 Источник Nasdaq GlobeNewswire

Veru Reports Fiscal 2023 Second Quarter Financial Results

11 май 2023 03:30:00 Источник Nasdaq GlobeNewswire

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

04 май 2023 05:30:01 Источник Nasdaq GlobeNewswire

Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital

03 май 2023 05:30:00 Источник Nasdaq GlobeNewswire

Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023

27 апр 2023 03:45:00 Источник Nasdaq GlobeNewswire

Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones

20 апр 2023 03:45:00 Источник Nasdaq GlobeNewswire

Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector

19 апр 2023 05:30:20 Источник Nasdaq GlobeNewswire